

Detecting and diagnosing cancer earlier is one of the key aspects of decreasing cancer-related mortality. One study estimated 15% fewer cancer-related deaths if those with stage IV cancers had been diagnosed at stage III.<sup>1</sup> In addition, 71% of cancer-related deaths in the US are due to cancers that are not routinely screened for<sup>1</sup>, highlighting the unmet need for better diagnostic tests.

Improving cancer survival rates and increasing the number of cancer cases being diagnosed earlier are priorities for many governments around the world. The UK NHS Long Term Plan includes £2.3 billion to increase the volume of diagnostic activity.<sup>2</sup> These factors are driving the demand for immunoassays to improve surveillance, diagnosis, and management of cancer.

Logical Biological can provide samples support the development of IVD diagnostic kits from the early stages of research and development to validation and commercialisation of finished IVD products and associated calibrators and controls.

Logical Biological can provide evaluation, clinical samples, or bulk volumes and collect samples prospectively based on your requirements. Our approach is to understand exactly what you need and provide material that meets your custom specification.

There are many serum tumour markers that can be used as an aid to detect cancer and monitor the progression of tumours and treatment. Logical Biological can supply plasma and serum to meet your requirements. Examples of customised material specifications we can fulfil are:

- Disease staged cancer serum or plasma
- Ø Pre-treatment donor samples
- Specified analyte concentration samples

The list of markers below is not exhaustive. Please contact us with requests for other markers.

## Markers available include

Cancer	Marker
Blood	Myeloma IgE
Breast	CA15-3
Cervical	Squamous Cell Carcinoma (SCC) CA125 / CA19-9
Colon	CEA
Gastric	CA72-4 / Gastrin-17 Pepsinogen 1 / Pepsinogen 2
Head and neck	Squamous Cell Carcinoma (SCC)
Liver	Alpha Feto Protein / Hepatocellular Carcinoma (HCC) / PIVKA2

Cancer	Marker
Lung - NSCLC - SCLC	CTSB / Small Cell Lung Cancer (SCLC) Cyfra 21-1 NSE
Ovarian	CA125 / HE4
Pancreatic	CA19-9
Prostate	PSA
Testicular	Alpha Feto Protein
Thyroid	Thyroglobulin (Tg)
Uterine	CA125
Various	HGFR

## **References:**

- 1. Examining Developments in Multicancer Early Detection: Highlights of New Clinical Data from Recent Conferences, AJMC, vol. 27, no. 19, 2021.
- 2. https://www.gov.uk/government/consultations/10-year-cancer-plan-call-for-evidence/10-year-cancer-plan-call-for-evidence [Accessed October, 2022].

## CONTACT US

- info@logicalbiological.com
- logicalbiological.

in

logicalbiological



+44 1304 799 747

Building 500, Discovery Park, Sandwich, Kent, CT13 9FE, UK